We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2022 to May 2024
By Michael Susin
AstraZeneca PLC said Thursday that it has entered into an agreement with KYM Biosciences Inc. regarding an exclusive license agreement for a gastric cancer treatment.
The Anglo-Swedish pharma major said it will be responsible for the research, development, manufacture and commercialization of CMG901 globally.
AstraZeneca will make an upfront payment of $63 million, additional development and sales-related milestone payments of up to $1.1 billion to KYM Biosciences and tiered royalties up to low double digits, it added.
The deal is expected to close in the first half of 2023.
MG901 is currently under a Phase 1 clinical trial for the treatment of Claudin 18.2-positive solid tumors, including gastric cancer.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
February 23, 2023 02:42 ET (07:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
